The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

Blood Reviews

Volumn 28, Issue 6, 2014, Pages 235-241

  Kaiser Guignard, Julie ^a   Canellini, Giorgia ^b   Lion, Niels ^b   Abonnenc, Mélanie ^b   Osselaer, Jean Claude ^b   Tissot, Jean Daniel ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Vaudois Regional Blood Transfusion Service   (Switzerland)

Author keywords

Amotosalen; Hemovigilance; Pathogen inactivation; Pathogen reduction; Platelet concentrates; Platelets; Riboflavin; Transfusion

Indexed keywords

AMOTOSALEN; RIBOFLAVIN; THROMBOCYTE CONCENTRATE; FUROCOUMARIN DERIVATIVE;

ADVERSE OUTCOME; BLOOD SAFETY; BLOOD TRANSFUSION REACTION; CLINICAL EFFECTIVENESS; GRAFT VERSUS HOST REACTION; HEMATOLOGICAL PROCEDURE; HUMAN; INFECTION RISK; NONHUMAN; PATHOGEN CLEARANCE; PATHOGEN INACTIVATION TECHNOLOGY; PATHOGEN REDUCTION; PATHOGEN REDUCTION SYSTEM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; THROMBOCYTE FUNCTION; THROMBOCYTE LIFESPAN; THROMBOCYTE TRANSFUSION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET C RADIATION; CYTOLOGY; DRUG EFFECTS; MICROBIOLOGY; PROCEDURES; RADIATION RESPONSE; STANDARDS; THROMBOCYTE; ULTRAVIOLET RADIATION;

BLOOD PLATELETS; FUROCOUMARINS; HUMANS; PLATELET TRANSFUSION; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 84923847705     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.07.005     Document Type: Article

References (86)

1. Jutzi M., Rüesch M., Mansouri Taleghani B. Introduction en Suisse de l'inactivation des agents pathogènes pour les concentrés plaquettaires. Forum Med Suisse 2013, 13:222-226.
2. Hoffmeister K.M., Felbinger T.W., Falet H., Denis C.V., Bergmeier W., Mayadas T.N., et al. The clearance mechanism of chilled blood platelets. Cell 2003, 112:87-97.
3. Jansen A.J., Josefsson E.C., Rumjantseva V., Liu Q.P., Falet H., Bergmeier W., et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIbalpha metalloproteinase-mediated cleavage in mice. Blood 2012, 119:1263-1273.
4. Hillyer C.D., Josephson C.D., Blajchman M.A., Vostal J.G., Epstein J.S., Goodman J.L. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematology Am Soc Hematol Educ Program 2003, 575-589.
5. Lin L., Cook D.N., Wiesehahn G.P., Alfonso R., Behrman B., Cimino G.D., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997, 37:423-435.
6. Alter H.J., Klein H.G. The hazards of blood transfusion in historical perspective. Blood 2008, 112:2617-2626.
7. Bryant B.J., Klein H.G. Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med 2007, 131:719-733.
8. Stramer S.L., Hollinger F.B., Katz L.M., Kleinman S., Metzel P.S., Gregory K.R., et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009, 49(Suppl. 2):1S-29S.
9. Klein H.G., Anderson D., Bernardi M.J., Cable R., Carey W., Hoch J.S., et al. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007, 47:2338-2347.
10. Webert K.E., Cserti C.M., Hannon J., Lin Y., Pavenski K., Pendergrast J.M., et al. Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008, 22:1-34.
11. Corash L., Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004, 33:1-7.
12. Grass J.A., Hei D.J., Metchette K., Cimino G.D., Wiesehahn G.P., Corash L., et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998, 91:2180-2188.
13. Ciaravino V., McCullough T., Cimino G. The role of toxicology assessment in transfusion medicine. Transfusion 2003, 43:1481-1492.
14. Cao H., Hearst J.E., Corash L., Wang Y. LC-MS/MS for the detection of DNA interstrand cross-links formed by 8-methoxypsoralen and UVA irradiation in human cells. Anal Chem 2008, 80:2932-2938.
15. Lai C., Cao H., Hearst J.E., Corash L., Luo H., Wang Y. Quantitative analysis of DNA interstrand cross-links and monoadducts formed in human cells induced by psoralens and UVA irradiation. Anal Chem 2008, 80:8790-8798.
16. Lin L., Dikeman R., Molini B., Lukehart S.A., Lane R., Dupuis K., et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004, 44:1496-1504.
17. Lin L., Hanson C.V., Alter H.J., Jauvin V., Bernard K.A., Murthy K.K., et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005, 45:580-590.
18. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001, 38:4-11.
19. http://www.aabb.org/resources/bct/eid/Documents/prt-systems-in-use-country-listing.pdf.
20. Marschner S., Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011, 38:8-18.
21. Goodrich R.P., Doane S., Reddy H.L. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010, 38:20-30.
22. Mohr H., Steil L., Gravemann U., Thiele T., Hammer E., Greinacher A., et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009, 49:2612-2624.
23. Sandgren P., Tolksdorf F., Struff W.G., Gulliksson H. In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method. Vox Sang 2011, 101:35-43.
24. Prowse C.V. Component pathogen inactivation: a critical review. Vox Sang 2013, 104:183-199.
25. Lozano M., Cid J. Pathogen inactivation: coming of age. Curr Opin Hematol 2013, 20:540-545.
26. Klein H.G., Glynn S.A., Ness P.M., Blajchman M.A. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Transfusion 2009, 49:1262-1268. NHLBI Working Group on Research Opportunities for the Pathogen Reduction/Inactivation of Blood Components.
27. Rasongles P., Angelini-Tibert M.F., Simon P., Currie C., Isola H., Kientz D., et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion. Transfusion 2009, 49:1083-1091.
28. Hauser L., Roque-Afonso A.M., Beyloune A., Simonet M., Deau Fischer B., Burin des Roziers N., et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood 2014, 123:796-797.
29. Prudent M., Sonego G., Abonnenc M., Tissot J.D., Lion N. LC-MS/MS analysis and comparison of oxidative damages on peptides induced by pathogen reduction technologies for platelets. J Am Soc Mass Spectrom 2014, 25:651-661.
30. Prudent M., d'Alessandro A., Cazenave J.P., Devine D.V., Gachet C., Greinacher A., et al. Proteome changes in platelets after pathogen inactivation - an interlaboratory consensus. Transfus Med Rev 2014, 28:72-83.
31. Weyrich A.S., Schwertz H., Kraiss L.W., Zimmerman G.A. Protein synthesis by platelets: historical and new perspectives. J Thromb Haemost 2009, 7:241-246.
32. Thon J.N., Devine D.V. Translation of glycoprotein IIIa in stored blood platelets. Transfusion 2007, 47:2260-2270.
33. Schubert P., Devine D.V. De novo protein synthesis in mature platelets: a consideration for transfusion medicine. Vox Sang 2010, 99:112-122.
34. Rollini F., Tello-Montoliu A., Angiolillo D.J. Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease. Platelets 2012, 23:537-551.
35. Harrison P., Mumford A. Screening tests of platelet function: update on their appropriate uses for diagnostic testing. Semin Thromb Hemost 2009, 35:150-157.
36. Hayward C.P. Diagnostic approach to platelet function disorders. Transfus Apher Sci 2008, 38:65-76.
37. Stroncek D.F., Rebulla P. Platelet transfusions. Lancet 2007, 370:427-438.
38. Panzer S., Jilma P. Methods for testing platelet function for transfusion medicine. Vox Sang 2011, 101:1-9.
39. Kehrel B.E., Brodde M.F. State of the art in platelet function testing. Transfus Med Hemother 2013, 40:73-86.
40. Chavarin P., Cognasse F., Argaud C., Vidal M., De Putter C., Boussoulade F., et al. In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System). Vox Sang 2011, 100:247-249.
41. Bochsen L., Johansson P.I., Kristensen A.T., Daugaard G., Ostrowski S.R. The influence of platelets, plasma and red blood cells on functional haemostatic assays. Blood Coagul Fibrinolysis 2011, 22:167-175.
42. Kattlove H.E., Alexander B., White F. The effect of cold on platelets. II. Platelet function after short-term storage at cold temperatures. Blood 1972, 40:688-696.
43. Rinder H.M., Smith B.R. In vitro evaluation of stored platelets: is there hope for predicting posttransfusion platelet survival and function?. Transfusion 2003, 43:2-6.
44. Cardigan R., Turner C., Harrison P. Current methods of assessing platelet function: relevance to transfusion medicine. Vox Sang 2005, 88:153-163.
45. van Rhenen D.J., Vermeij J., Mayaudon V., Hind C., Lin L., Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000, 79:206-214.
46. Murphy S., Rebulla P., Bertolini F., Holme S., Moroff G., Snyder E., et al. In vitro assessment of the quality of stored platelet concentrates. The BEST (Biomedical Excellence for Safer Transfusion) Task Force of the International Society of Blood Transfusion. Transfus Med Rev 1994, 8:29-36.
47. Holme S. Storage and quality assessment of platelets. Vox Sang 1998, 74(Suppl. 2):207-216.
48. Middelburg R.A., Roest M., Ham J., Coccoris M., Zwaginga J.J., van der Meer P.F. Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates. Transfusion 2013, 53:1780-1787.
49. Picker S.M., Speer R., Gathof B.S. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004, 44:320-329.
50. Bruchmuller I., Losel R., Bugert P., Corash L., Lin L., Kluter H., et al. Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets. Platelets 2005, 16:441-445.
51. Moog R., Frohlich A., Mayaudon V., Lin L. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days. J Clin Apher 2004, 19:185-191.
52. Janetzko K., Lin L., Eichler H., Mayaudon V., Flament J., Kluter H. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004, 86:239-245.
53. Isola H., Kientz D., Aleil B., Laeuffer P., Weil J., Wiesel M.L., et al. In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set. Vox Sang 2006, 90:128-130.
54. Jansen G.A., van Vliet H.H., Vermeij H., Beckers E.A., Leebeek F.W., Sonneveld P., et al. Functional characteristics of photochemically treated platelets. Transfusion 2004, 44:313-319.
55. Snyder E., Raife T., Lin L., Cimino G., Metzel P., Rheinschmidt M., et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004, 44:1732-1740.
56. Apelseth T.O., Bruserud O., Wentzel-Larsen T., Bakken A.M., Bjorsvik S., Hervig T. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion 2007, 47:653-665.
57. Wang C., Mody M., Herst R., Sher G., Freedman J. Flow cytometric analysis of platelet function in stored platelet concentrates. Transfus Sci 1999, 20:129-139.
58. Hagberg I.A., Akkok C.A., Lyberg T., Kjeldsen-Kragh J. Apheresis-induced platelet activation: comparison of three types of cell separators. Transfusion 2000, 40:182-192.
59. Vetlesen A., Mirlashari M.R., Torsheim I.A., Kjeldsen-Kragh J. Platelet activation and residual activation potential during storage of hyperconcentrated platelet products in two different platelet additive solutions. Transfusion 2005, 45:1349-1355.
60. Tynngard N., Johansson B.M., Lindahl T.L., Berlin G., Hansson M. Effects of intercept pathogen inactivation on platelet function as analysed by free oscillation rheometry. Transfus Apher Sci 2008, 38:85-88.
61. Lozano M., Galan A., Mazzara R., Corash L., Escolar G. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7days: assessment of hemostatic function under flow conditions. Transfusion 2007, 47:666-671.
62. Picker S.M., Schneider V., Gathof B.S. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies. Transfusion 2009, 49:1224-1232.
63. Kenet G., Lubetsky A., Shenkman B., Tamarin I., Dardik R., Rechavi G., et al. Cone and platelet analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998, 101:255-259.
64. Osende J.I., Fuster V., Lev E.I., Shimbo D., Rauch U., Marmur J.D., et al. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 2001, 103:1488-1491.
65. Cazenave J.P., Ohlmann P., Cassel D., Eckly A., Hechler B., Gachet C. Preparation of washed platelet suspensions from human and rodent blood. Methods Mol Biol 2004, 272:13-28.
66. Hechler B., Ohlmann P., Chafey P., Ravanat C., Eckly A., Maurer E., et al. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion 2013, 53:1187-1200.
67. Shrivastava M. The platelet storage lesion. Transfus Apher Sci 2009, 41:105-113.
68. Cognasse F., Osselaer J.C., Payrat J.M., Chavarin P., Corash L., Garraud O. Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment. Transfusion 2008, 48:809-813.
69. Infanti L., Stebler C., Job S., Ruesch M., Gratwohl A., Irsch J., et al. Pathogen-inactivation of platelet components with the INTERCEPT Blood System: a cohort study. Transfus Apher Sci 2011, 45:175-181.
70. Cazenave J.P., Isola H., Waller C., Mendel I., Kientz D., Laforet M., et al. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011, 51:622-629.
71. de Wildt-Eggen J., Nauta S., Schrijver J.G., van Marwijk Kooy M., Bins M., van Prooijen H.C. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 2000, 40:398-403.
72. Osselaer J.C., Doyen C., Defoin L., Debry C., Goffaux M., Messe N., et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009, 49:1412-1422.
73. Osselaer J.C., Cazenave J.P., Lambermont M., Garraud O., Hidajat M., Barbolla L., et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008, 94:315-323.
74. Janetzko K., Cazenave J.P., Kluter H., Kientz D., Michel M., Beris P., et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005, 45:1443-1452.
75. Kerkhoffs J.L., van Putten W.L., Novotny V.M., Te Boekhorst P.A., Schipperus M.R., Zwaginga J.J., et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010, 150:209-217.
76. Lozano M., Knutson F., Tardivel R., Cid J., Maymo R.M., Lof H., et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7d prior to transfusion. Br J Haematol 2011, 153:393-401.
77. McCullough J., Vesole D.H., Benjamin R.J., Slichter S.J., Pineda A., Snyder E., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004, 104:1534-1541.
78. Sigle J.P., Infanti L., Studt J.D., Martinez M., Stern M., Gratwohl A., et al. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components. Transfusion 2013, 53:1788-1797.
79. van Rhenen D., Gulliksson H., Cazenave J.P., Pamphilon D., Ljungman P., Kluter H., et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003, 101:2426-2433.
80. Daly P.A., Schiffer C.A., Aisner J., Wiernik P.H. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 1980, 243:435-438.
81. Slichter S.J., Kaufman R.M., Assmann S.F., McCullough J., Triulzi D.J., Strauss R.G., et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010, 362:600-613.
82. Cook R.J., Heddle N.M. Clinical trials evaluating pathogen-reduced platelet products: methodologic issues and recommendations. Transfusion 2013, 53:1843-1855.
83. Corash L., Sherman C.D. Evaluation of platelet transfusion clinical trials. Br J Haematol 2011, 153:529-531. [author reply 31-2].
84. Dumont L.J., AuBuchon J.P., Whitley P., Herschel L.H., Johnson A., McNeil D., et al. Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study. Transfusion 2002, 42:847-854.
85. Vamvakas E.C. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012, 102:302-316.
86. Cid J., Escolar G., Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012, 103:322-330.